- Report
- May 2024
- 128 Pages
Global
From €5931EUR$6,499USD£5,057GBP
- Report
- April 2025
- 194 Pages
Global
From €5339EUR$5,850USD£4,552GBP
- Report
- February 2025
- 247 Pages
Global
From €2282EUR$2,500USD£1,945GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1825EUR$2,000USD£1,556GBP
- Report
- February 2024
- 200 Pages
Global
From €7255EUR$7,950USD£6,186GBP
- Drug Pipelines
- July 2020
- 440 Pages
Global
From €1825EUR$2,000USD£1,556GBP
- Report
- August 2022
Global
From €995EUR$1,090USD£848GBP
- Report
- October 2024
- 99 Pages
Global
From €3500EUR$4,108USD£3,089GBP
The Traumatic Brain Injury Drug market is a subset of the Central Nervous System Drugs market. It is composed of drugs used to treat the physical and psychological effects of traumatic brain injuries (TBIs). These drugs are used to reduce inflammation, improve cognitive function, and reduce the risk of secondary injury. Commonly used drugs include corticosteroids, anticonvulsants, and antidepressants. Additionally, some drugs are used to treat the psychological effects of TBIs, such as anxiety, depression, and post-traumatic stress disorder.
The Traumatic Brain Injury Drug market is highly competitive, with many companies offering a variety of drugs. Some of the major players in the market include Pfizer, Novartis, Merck, Johnson & Johnson, and GlaxoSmithKline. Other companies include Sanofi, AstraZeneca, and Eli Lilly. Show Less Read more
